Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.66 |
| ▸ | MMP7 known ✓ | P09237 | 1/20 | 0.65 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.65 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.65 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | RECQL | P46063 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | THRB | P10828 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 7/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26628251 | 0.99 | TDP1 (1.00) | TDP1KDM4ERECQLHPGDMEN1 | |
| SCHEMBL19555132 | 0.99 | TDP1 (1.00) | TDP1KDM4ERECQLHPGDMEN1 | |
| SCHEMBL26597994 | 0.99 | TDP1 (1.00) | TDP1KDM4ERECQLHPGDMEN1 | |
| SCHEMBL30567156 | 0.99 | TDP1 (1.00) | TDP1KDM4ERECQLHPGDMEN1 | |
| SCHEMBL29537520 | 0.99 | TDP1 (1.00) | TDP1KDM4ERECQLHPGDMEN1 | |
| SCHEMBL23247761 | 0.85 | TDP1 (0.78) | TDP1KDM4ERECQLHPGDMEN1 | |
| SCHEMBL29487299 | 0.85 | TDP1 (0.78) | TDP1KDM4ERECQLHPGDMEN1 | |
| SCHEMBL4015 | 0.84 | TDP1 (0.73) | TDP1KDM4ERECQLHPGDMEN1 | |
| Hydrochloric Acid SCHEMBL20398184 | 0.82 | TDP1 (0.71) | TDP1KDM4ERECQLHPGDMEN1 | |
| Methacycline SCHEMBL5445227 | 0.82 | TDP1 (0.70) | TDP1KDM4ERECQLHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| CN-119979686-A | Molecular hopper | 牛津大学创新有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025082254-A1 | ANTI-HUMAN HHLA2 NANOBODY AND USE THEREOF | 科辉智药(深圳)新药研究中心有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-113861268-B | Cell penetrating peptides and methods of making and using the same | 恩特拉达治疗学股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-112384162-B | Bone material dispensing system with locking member | 华沙整形外科股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119136833-A | Membrane translocation domain and uses thereof | 俄亥俄州创新基金会 | 2024-12-13 | — | — | CN | disclosed |
| CN-112888944-B | Molecular hopper | 牛津大学创新有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-119013042-A | Companion diagnosis of human CEACAM1 targeted therapeutics | 布里格姆及妇女医院股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118873822-A | Treatment of gastrointestinal disorders with TNF inhibitors | 比奥拉治疗股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118613231-A | Orthodontic device for delivering active agents | 斯米利奥公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-110167589-B | Treatment of gastrointestinal disorders using integrin inhibitors | 比奥拉治疗股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-115634081-A | Bone material dispensing system and method of use | 华沙整形外科股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-115429877-A | TIGIT binding agents and uses thereof | 梅里奥生物制药第五有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-115038451-A | Multimodal compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115003279-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114955210-A | Container for storing, mixing and transporting bone material | 华沙整形外科股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114765956-A | Combinations of zidovudine and tetracycline antibiotics | 赫尔普百治疗有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-109071620-B | TIGIT binding agents and uses thereof | 梅里奥生物制药第五有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-108786619-B | Bone material dispensing apparatus and method | 华沙整形外科股份有限公司 | 2022-03-04 | — | — | CN | disclosed |